| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10917852 | Radiotherapy and Oncology | 2016 | 5 Pages |
Abstract
Boost RT for ERÂ +Â ESBC patients was cost-effective over a wide range of assumptions and inputs over commonly accepted willingness-to pay-thresholds, but particularly in women at higher risk for LR.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Nataniel H. Lester-Coll, Charles E. Rutter, Suzanne B. Evans,